Novavax (NVAX) Capital Expenditures Growth (1y) (2011 - 2026)
Novavax (NVAX) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 143.40% |
| 10 | Novavax | 1.25 Bn | 455.46 Mn | 108.82 Mn | -20.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.38% |
| Dec 31, 2025 | 1,076.10% |
| Sep 30, 2025 | -223.55% |
| Jun 30, 2025 | 78.16% |
| Mar 31, 2025 | 32.04% |
| Dec 31, 2024 | 98.53% |
| Sep 30, 2024 | -97.56% |
| Jun 30, 2024 | -172.70% |
| Mar 31, 2024 | -67.85% |
| Dec 31, 2023 | 40.37% |
| Sep 30, 2023 | -38.87% |
| Jun 30, 2023 | 104.79% |
| Mar 31, 2023 | -77.67% |
| Dec 31, 2022 | -62.84% |
| Sep 30, 2022 | 441.70% |
| Jun 30, 2022 | -184.74% |
| Mar 31, 2022 | 85.39% |
| Dec 31, 2021 | -206.05% |
| Sep 30, 2021 | 39.70% |
| Jun 30, 2021 | 428.23% |